Tools / Drugs Diphenhydramine hydrochloride Sold as Benadryl, Benylin, Benadryl Preservative Free. Every FDA application for this active ingredient: 4 branded and 89 generic.
As of Nov 22, 2026, FDA lists 93 applications for Diphenhydramine hydrochloride (sold as Benadryl, Benylin, Benadryl Preservative Free), first approved Mar 4, 1946, with 1 new use approved and 0 published complete response letters.
Applications : 93 New use approved : 1 Complete response letters : 0 Medicare spending, 2025 : $1.7M Mechanism of action and target, from ChEMBL Uses, approved and in trials Each condition ChEMBL records for this drug, with the furthest stage reached and the trials it cites; approved means approved for that use somewhere, not necessarily in the US
Motion sickness Approved
Dizziness Approved
Fever Approved NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history Approved Application Sponsor Supplements Marketing Mar 4, 1946 Benadryl NDA 5845 · New molecular entity Mcneil Cons10 Discontinued Mar 6, 1947 Benadryl NDA 6146 · New dosage form Mcneil Cons6 Discontinued Dec 30, 1957 Benadryl Preservative Free NDA 9486 · New dosage form Mcneil Cons12 Discontinued May 9, 1972 Diphenhydramine Hydrochloride ANDA 80762 IVAX Pharmaceuticals0 Discontinued May 31, 1972 Diphenhydramine Hydrochloride ANDA 80519 ALRA1 Discontinued Aug 7, 1972 Diphenhydramine Hydrochloride ANDA 80577 Wyeth-Ayerst4 Discontinued Aug 24, 1972 Diphenhydramine Hydrochloride ANDA 80738 Heritage Pharmaceuticals15 Discontinued Sep 27, 1972 Diphenhydramine Hydrochloride ANDA 80727 Heritage Pharmaceuticals10 Discontinued Nov 3, 1972 Diphenhydramine Hydrochloride ANDA 80832 Fosun Pharma17 Discontinued Nov 27, 1972 Diphenhydramine Hydrochloride ANDA 80817 West-Ward Pharms Int17 Marketed Dec 20, 1972 Diphenhydramine Hydrochloride ANDA 80643 Roxane Laboratories6 Discontinued Jan 12, 1973 Diphenhydramine Hydrochloride ANDA 83087 MK Laboratories1 Discontinued Jan 12, 1973 Diphenhydramine Hydrochloride ANDA 83088 MK Laboratories2 Discontinued Feb 28, 1973 Diphenhydramine Hydrochloride ANDA 80728 Watson Laboratories11 Discontinued Aug 13, 1973 Diphenhydramine Hydrochloride ANDA 80800 Whiteworth Town Plsn2 Discontinued Oct 12, 1973 Diphenhydramine Hydrochloride ANDA 83183 Hikma Pharmaceuticals0 Discontinued Oct 12, 1973 Diphenhydramine Hydrochloride ANDA 83634 NexGen Pharma0 Discontinued Oct 25, 1973 Diphenhydramine Hydrochloride ANDA 83567 Hikma Pharmaceuticals3 Discontinued Nov 14, 1973 Diphenhydramine Hydrochloride ANDA 80807 Impax Laboratories1 Discontinued Jan 18, 1974 Diphenhydramine Hydrochloride ANDA 80592 Valeant Pharmaceuticals International0 Discontinued Jan 29, 1974 Diphenhydramine Hydrochloride, Diphenhydramine Hydrochloride Preservative Free ANDA 80873 Dr. Reddy's Laboratories13 Discontinued Feb 13, 1974 Diphenhydramine Hydrochloride ANDA 80868 Lannett1 Discontinued Dec 19, 1974 Diphenhydramine Hydrochloride ANDA 84506 Mutual Pharmaceutical10 Discontinued Feb 13, 1975 Diphenhydramine Hydrochloride ANDA 83797 Watson Laboratories0 Discontinued Mar 15, 1976 Diphenhydramine Hydrochloride Preservative Free ANDA 84094 International Medication Systems12 Discontinued Jun 29, 1976 Diphenhydramine Hydrochloride ANDA 85083 Watson Laboratories17 Discontinued Jul 29, 1976 Diphenhydramine Hydrochloride ANDA 85138 Watson Laboratories0 Discontinued Sep 22, 1977 Diphenhydramine Hydrochloride ANDA 85621 KV Pharmaceutical0 Discontinued Jan 25, 1979 Diphenhydramine Hydrochloride ANDA 80822 Bel Mar0 Discontinued Feb 8, 1979 Diphenhydramine Hydrochloride ANDA 86543 Newtron Pharmaceuticals0 Discontinued Feb 8, 1979 Diphenhydramine Hydrochloride ANDA 86544 Newtron Pharmaceuticals0 Discontinued Feb 26, 1979 Diphen ANDA 84640 USL Pharma9 Discontinued Oct 30, 1979 Diphenhydramine Hydrochloride ANDA 85874 Teva Pharmaceutical Industries0 Discontinued Mar 31, 1981 Diphenhydramine Hydrochloride ANDA 87066 Lyphomed0 Discontinued Dec 7, 1981 Diphenhydramine Hydrochloride ANDA 87630 Vangard Labs0 Discontinued Jan 25, 1982 Diphenhydramine Hydrochloride ANDA 83237 Purepac Pharmaceutical0 Discontinued Feb 10, 1982 Diphenhydramine Hydrochloride ANDA 87513 Pharmaceutical Associates9 Marketed Oct 27, 1982 Diphenhydramine Hydrochloride ANDA 88034 Vangard Labs2 Discontinued Jan 27, 1983 Diphenhydramine Hydrochloride ANDA 87977 LNK2 Discontinued Jan 27, 1983 Diphenhydramine Hydrochloride ANDA 87978 LNK3 Discontinued Oct 3, 1983 Belix ANDA 86586 Halsey Drug0 Discontinued Jun 5, 1986 Beldin ANDA 89179 Halsey Drug2 Discontinued Jan 2, 1987 Diphenhydramine Hydrochloride ANDA 89489 Sun Pharmaceutical Industries8 Discontinued Jan 2, 1987 Diphenhydramine Hydrochloride ANDA 89488 Sun Pharmaceutical Industries8 Discontinued Sep 28, 1990 Diphenhydramine Hydrochloride ANDA 72416 ScieGen Pharmaceuticals3 Discontinued Jun 28, 1993 Diphen ANDA 70118 Morton Grove Pharmaceuticals2 Discontinued Nov 20, 1998 Diphenhydramine Hydrochloride ANDA 40140 Hospira4 Discontinued May 28, 2002 Diphenhydramine Hydrochloride ANDA 40466 APP Pharmaceuticals0 Marketed Jul 12, 2005 Diphenhydramine Hydrochloride ANDA 40498 PharmoBedient1 Discontinued Mar 26, 2013 Diphenhydramine Hydrochloride Preservative Free ANDA 91526 Fresenius Kabi USA0 Marketed Aug 22, 2018 Diphenhydramine Hydrochloride ANDA 205723 Micro Labs2 Marketed Mar 20, 2024 Diphenhydramine Hydrochloride ANDA 218448 Gland Pharma0 Marketed Jun 24, 2025 Diphenhydramine Hydrochloride ANDA 205336 Avet Lifesciences0 Marketed Aug 22, 2025 Diphenhydramine Hydrochloride ANDA 219845 Micro Labs0 Marketed Nov 14, 2025 Diphenhydramine Hydrochloride ANDA 205337 Avet Lifesciences0 Marketed Jun 17, 2026 Diphenhydramine Hydrochloride ANDA 219470 Annora Pharma0 Marketed — Benylin NDA 6514 Parke-Davis0 Discontinued — Vicks Formula 44 ANDA 70524 Warner Chilcott0 Discontinued — Hydramine ANDA 70205 Alpharma US Pharmaceuticals0 Discontinued — Diphenhydramine Hydrochloride ANDA 70497 Alpharma US Pharmaceuticals0 Discontinued — Antitussive ANDA 71292 Perrigo0 Discontinued — Silphen ANDA 72646 Lannett0 Discontinued — Diphenhydramine Hydrochloride ANDA 73611 Cumberland Swan0 Discontinued — Diphenhydramine Hydrochloride ANDA 83027 PVT FORM0 Discontinued — Diphenhydramine Hydrochloride Preservative Free ANDA 80586 Abraxis Pharmaceuticals0 Discontinued — Diphenhydramine Hydrochloride ANDA 80596 Valeant Pharmaceuticals International0 Discontinued — Diphenhydramine Hydrochloride ANDA 80635 Roxane Laboratories0 Discontinued — Hydramine ANDA 80763 Alpharma US Pharmaceuticals0 Discontinued — Diphenhydramine Hydrochloride ANDA 80845 Fosun Pharma0 Discontinued — Diphenhydramine Hydrochloride ANDA 80939 Lannett0 Discontinued — Diphenhydramine Hydrochloride ANDA 83061 Perrigo0 Discontinued — Diphenhydramine Hydrochloride ANDA 83063 Perrigo0 Discontinued — Diphenhydramine Hydrochloride ANDA 83275 ANABOLIC0 Discontinued — Diphenhydramine Hydrochloride ANDA 83441 Whiteworth Town Plsn2 Discontinued — Diphenhydramine Hydrochloride ANDA 83533 Watson Laboratories0 Discontinued — Diphenhydramine Hydrochloride ANDA 83674 Bundy0 Discontinued — Diphenhydramine Hydrochloride ANDA 83953 Heather0 Discontinued — Diphenhydramine Hydrochloride ANDA 84524 Heather0 Discontinued — Diphenhydramine Hydrochloride ANDA 85150 Purepac Pharmaceutical0 Discontinued — Diphenhydramine Hydrochloride ANDA 85156 Purepac Pharmaceutical0 Discontinued — Diphenhydramine Hydrochloride ANDA 85287 PVT FORM0 Discontinued — Diphenhydramine Hydrochloride ANDA 85701 Elkins-Sinn0 Discontinued — Diphenhydramine Hydrochloride ANDA 89101 Pioneer Pharmaceuticals0 Discontinued — Diphenhydramine Hydrochloride ANDA 86874 Lederle Laboratories2 Discontinued — Diphenhydramine Hydrochloride ANDA 86875 Lederle Laboratories0 Discontinued — Diphenhydramine Hydrochloride ANDA 86937 Lederle Laboratories0 Discontinued — Diphenhydramine Hydrochloride ANDA 87914 Halsey Drug0 Discontinued — Diphenhydramine Hydrochloride ANDA 87941 Cenci0 Discontinued — Dibenil ANDA 88304 Cenci0 Discontinued — Diphenhydramine Hydrochloride ANDA 88680 NASKA0 Discontinued — Diphenhydramine Hydrochloride ANDA 88880 Pioneer Pharmaceuticals0 Discontinued — Diphenhydramine Hydrochloride ANDA 89040 Superpharm0 Discontinued — Diphenhydramine Hydrochloride ANDA 89041 Superpharm0 Discontinued
Show all 93CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name Product Part Spending, 2025 Change Beneficiaries Diphenhydramine HCl Part D $1.4M +3% 26,660 Diphenhydramine HCL Part B $346K −10% 89,993
What state Medicaid programs paid pharmacies in 2025, before rebates, by product name; see every drug
Diphenhydramine $46.0M for 1,102,251 prescriptions, −17% on 2024 Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change Diphenhydramine 50 mg/mL vial: $0.874 per mL Generic · −3% in a year How its trials ended 122 ClinicalTrials.gov studies testing it, classified by TrialPanorama , partly automatically, so some labels are wrong Of the 41 whose ending is known, 34% met their primary endpoint, 17% missed it and 49% stopped early.
Completed, result not reported 52 43%Completed, result not reported Count52 Share43% Ongoing 25 20%Ongoing Count25 Share20% Met its primary endpoint 14 11%Met its primary endpoint Count14 Share11% Stopped: other or unclear 10 8%Stopped: other or unclear Count10 Share8% Missed its primary endpoint 7 6%Missed its primary endpoint Count7 Share6% Stopped: enrollment or feasibility 4 3%Stopped: enrollment or feasibility Count4 Share3% Status unknown 4 3%Status unknown Count4 Share3% Stopped: safety 2 2%Stopped: safety Count2 Share2% Stopped: sponsor or business decision 2 2%Stopped: sponsor or business decision Count2 Share2% Stopped: lack of efficacy 1 1%Stopped: lack of efficacy Count1 Share1% Stopped: funding 1 1%Stopped: funding Count1 Share1% Trials that missed or stopped early NCT04918147 Stopped early: “The study was terminated early based on disease flare/lack of efficacy in the early phase of the trial.” Adverse event reports (FAERS) Cases reported to FDA naming this drug as the primary suspect, 2025 Q4 to 2026 Q3, from FDA's quarterly files . A report does not show the drug caused the event.
Cases 826
Serious 364 (44%)
Deaths reported 212
By quarter 2025 Q4: 150 · 2026 Q1: 270 · 2026 Q2: 312 · 2026 Q3: 94
Most reported reactions Toxicity to various agents (335), Seizure (206), Intentional overdose (78), Completed suicide (72), Drug abuse (44), Overdose (42), Intentional product misuse (33), Intentional product use issue (29), Tachycardia (25), Postmortem blood drug level increased (24) FDA drug safety communications 2 communications since 2020 that name this drug; see all communications 91 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all Study Phase Status Posted Neoadjuvant Finotonlimab Plus TP Regimen in Locally Advanced INI-1-Deficient Sinonasal Carcinoma SMARCB1-Deficient Sinonasal Carcinoma · Eye & ENT Hospital of Fudan University Phase 2 Recruiting Nov 10, 2026 A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010) Lymphoma, Large B-Cell, Diffuse, Diffuse Large B-Cell Lymphoma · Merck Sharp & Dohme LLC Phase 2 / Phase 3 Not yet recruiting Nov 5, 2026 Dexamethasone De-Escalation in Neoadjuvant Chemoimmunotherapy for Triple-Negative Breast Cancer Triple Negative Breast Cancer, Triple Negative Breast Cancer (TNBC) · Washington University School of Medicine Phase 2 Not yet recruiting Nov 3, 2026 A Clinical Trial of Gocatamig (MK-6070) With Durvalumab in Participants With Small Cell Lung Cancer (MK-6070-004) Small Cell Lung Cancer · Merck Sharp & Dohme LLC Phase 3 Not yet recruiting Nov 2, 2026 A Study of MC001 in Patients With Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) and Other Folate Receptor Alpha (FRα)-Expressing Solid Tumors Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumor Cancer · Medicovestor, Inc Phase 1 Not yet recruiting Nov 2, 2026 Efficacy and Safety of Obinutuzumab Beta in Primary IgA Nephropathy With Active Pathological Lesions Primary IgA Nephropathy · Ruijin Hospital Phase 4 Not yet recruiting Oct 22, 2026 A Clinical Trial of MK-6255 to Treat Endometrial and Ovarian Cancer (MK-6255-001) Ovarian Neoplasms, Endometrial Neoplasms · Merck Sharp & Dohme LLC Phase 1 Not yet recruiting Oct 13, 2026 Umbilical Cord Blood Infusion to Promote Hematopoietic and Immune Reconstitution in Children With Relapsed or Refractory Malignant Solid Tumors Pediatric Cancer, Solid Tumor Cancer · Tianjin Medical University Cancer Institute and Hospital Not applicable Not yet recruiting Oct 8, 2026
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered. Drugs@FDA